Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADPT

ADPT - Adaptive Biotechnologies Corp Stock Price, Fair Value and News

3.88USD+0.06 (+1.57%)Market Closed
Watchlist

Market Summary

USD3.88+0.06
Market Closed
1.57%

ADPT Alerts

  • ARK Investment Management LLC reported owning 8.85% of ADPT [2024-01-29]

ADPT Stock Price

View Fullscreen

ADPT RSI Chart

ADPT Valuation

Market Cap

561.7M

Price/Earnings (Trailing)

-2.87

Price/Sales (Trailing)

3.13

Price/Free Cashflow

-3.28

ADPT Price/Sales (Trailing)

ADPT Profitability

Return on Equity

-54.17%

Return on Assets

-27.3%

Free Cashflow Yield

-30.5%

ADPT Fundamentals

ADPT Revenue

Revenue (TTM)

179.7M

Rev. Growth (Yr)

-20.72%

Rev. Growth (Qtr)

-22.5%

ADPT Earnings

Earnings (TTM)

-195.9M

Earnings Growth (Yr)

-11.08%

Earnings Growth (Qtr)

-5.21%

Breaking Down ADPT Revenue

Last 7 days

1.9%

Last 30 days

-12.5%

Last 90 days

-10.7%

Trailing 12 Months

-56.3%

How does ADPT drawdown profile look like?

ADPT Financial Health

Current Ratio

4.67

Debt/Equity

0.35

Debt/Cashflow

-1.26

ADPT Investor Care

Shares Dilution (1Y)

1.23%

Diluted EPS (TTM)

-1.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023184.3M189.6M179.7M0
2022154.5M159.7M168.0M185.3M
2021115.9M133.4M146.6M154.3M
202093.3M92.2M92.4M98.4M
201958.6M69.2M78.1M85.1M
201842.8M47.1M51.4M55.7M
201700038.4M

Tracking the Latest Insider Buys and Sells of Adaptive Biotechnologies Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 13, 2023
neupert peter m
acquired
84,000
0.84
100,000
-
Nov 16, 2023
piskel kyle
sold
-1,069
4.13
-259
principal accounting officer
Aug 08, 2023
sood nitin
sold
-68,997
6.54
-10,550
chief commercial officer, mrd
Aug 07, 2023
sood nitin
sold
-38,320
6.78
-5,652
chief commercial officer, mrd
Jun 20, 2023
peterson tycho
sold
-1,098,580
8.14
-134,961
chief financial officer
Jun 20, 2023
peterson tycho
acquired
985,215
7.3
134,961
chief financial officer
Jun 15, 2023
peterson tycho
acquired
104,594
7.3
14,328
chief financial officer
Jun 15, 2023
peterson tycho
sold
-597,100
8.53
-70,000
chief financial officer
Jun 02, 2023
peterson tycho
sold
-272,080
7.16
-38,000
chief financial officer
Apr 11, 2023
adams r mark
sold
-19,918
8.63
-2,308
chief operating officer

1–10 of 50

Which funds bought or sold ADPT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-5.14
-247,000
1,436,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-583
-
-%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
627
627
-%
Feb 15, 2024
GTS SECURITIES LLC
new
-
72,104
72,104
-%
Feb 15, 2024
TOWNSQUARE CAPITAL LLC
sold off
-100
-65,123
-
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-0.35
-55,805
480,677
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
451
689,311
863,526
-%
Feb 15, 2024
BARCLAYS PLC
added
67.51
375,000
1,116,000
-%
Feb 15, 2024
Pier Capital, LLC
reduced
-1.11
-434,491
3,484,420
0.50%
Feb 14, 2024
PUTNAM INVESTMENTS LLC
reduced
-58.86
-664,517
390,020
-%

1–10 of 45

Are Funds Buying or Selling ADPT?

Are funds buying ADPT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADPT
No. of Funds

Unveiling Adaptive Biotechnologies Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
viking global investors lp
20.7%
29,993,708
SC 13G/A
Feb 13, 2024
vanguard group inc
8.82%
12,767,684
SC 13G/A
Jan 29, 2024
ark investment management llc
8.85%
12,806,513
SC 13G/A
Jan 26, 2024
blackrock inc.
7.9%
11,421,554
SC 13G
Feb 13, 2023
blackrock inc.
8.7%
12,374,197
SC 13G
Feb 10, 2023
ark investment management llc
6.43%
9,201,245
SC 13G
Feb 09, 2023
vanguard group inc
8.25%
11,794,168
SC 13G/A
Sep 12, 2022
price t rowe associates inc /md/
2.9%
4,081,518
SC 13G/A
Feb 14, 2022
matrix capital management company, lp
8.20%
11,572,590
SC 13G/A
Feb 14, 2022
viking global investors lp
21.3%
29,993,708
SC 13G/A

Recent SEC filings of Adaptive Biotechnologies Corp

View All Filings
Date Filed Form Type Document
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
SC 13G
Major Ownership Report
Dec 15, 2023
4
Insider Trading
Nov 20, 2023
4
Insider Trading

Peers (Alternatives to Adaptive Biotechnologies Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Adaptive Biotechnologies Corp News

Latest updates
MarketBeat19 Feb 202407:20 am
InvestorsObserver15 Feb 202403:59 pm

Adaptive Biotechnologies Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-22.5%37,919,00048,926,00037,647,00055,198,00047,830,00043,660,00038,620,00037,930,00039,467,00038,505,00038,442,00030,185,00026,299,00020,988,00020,910,00024,209,00026,058,00022,138,00012,666,00017,192,00017,188,000
Costs and Expenses-8.1%88,875,00096,744,00094,840,00094,384,00093,261,00096,162,000101,687,00099,526,00095,792,00088,270,00079,722,00074,424,00063,348,00057,897,00055,530,00048,397,00044,111,00038,243,00032,711,00031,336,00026,349,000
  S&GA Expenses-14.2%20,493,00023,872,00022,308,00023,716,00021,513,00024,281,00026,093,00026,696,00024,949,00023,216,00020,604,00018,545,00014,474,00014,332,00014,007,00012,640,0009,099,0008,897,0007,817,0008,071,0006,039,000
  R&D Expenses-11.5%28,533,00032,237,00032,601,00031,222,00035,658,00037,037,00037,839,00034,699,00036,072,00037,800,00033,772,00035,831,00030,314,00025,992,00023,935,00021,189,00020,506,00016,527,00012,483,00011,067,0009,783,000
EBITDA Margin-------1.19-1.25-1.26---1.07-1.26-0.50-0.50-0.50-0.54-----
Interest Expenses1.3%3,652,0003,605,0003,531,000-653,000----------------
Income Taxes-------------688,000-1,481,000-323,000------
EBT Margin-------1.30-1.34-1.34---1.26-1.49-0.74-0.74-0.74-0.81-----
Net Income-5.2%-50,300,000-47,810,000-57,699,000-40,128,000-45,281,000-52,046,000-62,736,000-58,084,500-55,903,000-55,998,000-40,642,000-44,570,000-36,719,000-33,535,000-31,403,000-20,611,000-13,950,000-15,659,000-18,386,000-13,271,000-8,292,000
Net Income Margin-8.3%-1.09-1.01-1.06-1.08-1.30-1.43-1.51-1.36-1.34-1.33-1.34-1.49---------
Free Cashflow-81.5%-49,462,000-27,253,000-62,076,000-32,561,000-47,840,000-52,363,000-67,530,000-63,071,000-58,062,000-59,254,000-74,086,000-49,214,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-6.1%7187657918578848078589239931,0331,0721,1161,095855875912917601467333340
  Current Assets-8.7%435477501562564439419403467644765727877600585613601442-181-
    Cash Equivalents-18.8%89.0010995.0090.0021876.0011513912218417412349736521397.0075.0048.00-55.00-
  Inventory2.8%19.0019.0020.0014.0017.0019.0021.0019.0018.0019.0017.0014.0011.0011.0011.009.009.008.00-8.00-
  Net PPE-3.3%77.0079.0081.0083.0087.0087.0086.0085.0088.0075.0056.0040.0031.0027.0025.0060.0047.0022.00-19.00-
  Goodwill0%119119119119119119119119119119119119119119119119119119-119-
Liabilities-3.4%35636936839339628830531934134034637332032532334133132417730.0029.00
  Current Liabilities-2.1%93.0095.0090.0011010411111511412211710710510193.0078.0078.0073.0075.00-23.00-
  Long Term Debt-127--125-----------------
    LT Debt, Non Current-127--125-----------------
Shareholder's Equity-8.6%36239642446448851855360465269372674377553055257158646.0041.0038.0035.00
  Retained Earnings-4.9%-1,074-1,024-976-919-878-833-781-718-657-601-552-511-467-430-396-365-344-330--295-
  Additional Paid-In Capital1.1%1,4371,4221,4031,3871,3731,3581,3401,3241,3091,2951,2771,2541,24195894593693046.00-38.00-
Shares Outstanding0.1%145145144143143142142141140140139131---------
Minority Interest-37.7%-0.09-0.07-0.07-0.07-0.030.000.000.000.000.000.00----------
Float------899---3,951---3,590---2,009---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-98.2%-46,684-23,556-59,152-30,019-42,408-47,065-64,453-53,826-43,443-37,213-58,245-39,844-47,156-31,077-31,606-26,791-30,138-15,970278,303-5,410-11,686
  Share Based Compensation-11.6%15,33617,34514,67114,29414,14214,18012,86111,87511,64311,2498,4847,2306,4706,4004,6753,4113,3353,3323,0463,0462,553
Cashflow From Investing-30.0%26,13837,32362,979-97,54458,0154,74637,68867,212-21,26841,44793,819-340,049-97,246177,492142,75946,680-260,852-45,349-222,17627,6295,133
Cashflow From Financing-98.8%17.001,4696726.00125,5203,9902,7493,2782,9266,32814,6146,253276,0386,3374,9591,746319,550-1,50412427857.00

ADPT Income Statement

2023-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Revenue$ 37,919$ 47,830$ 124,492$ 130,110
Operating expenses    
Cost of revenue19,34614,90755,93741,320
Research and development28,53335,65893,371110,534
Sales and marketing20,49321,51366,67371,887
General and administrative20,07520,75563,20866,099
Amortization of intangible assets4284281,2701,270
Total operating expenses88,87593,261280,459291,110
Loss from operations(50,956)(45,431)(155,967)(161,000)
Interest and other income, net4,28276510,9181,454
Interest expense(3,652)(653)(10,788)(653)
Net loss(50,326)(45,319)(155,837)(160,199)
Add: Net loss attributable to noncontrolling interest263828136
Net loss attributable to Adaptive Biotechnologies Corporation$ (50,300)$ (45,281)$ (155,809)$ (160,063)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic$ (0.35)$ (0.32)$ (1.08)$ (1.12)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic144,704,868142,928,654144,208,940142,334,342
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted$ (0.35)$ (0.32)$ (1.08)$ (1.12)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted144,704,868142,928,654144,208,940142,334,342

ADPT Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 88,713$ 90,030
Short-term marketable securities (amortized cost of $282,669 and $412,282, respectively)282,419408,166
Accounts receivable, net31,21140,057
Inventory19,49014,453
Prepaid expenses and other current assets13,4049,440
Total current assets435,237562,146
Long-term assets  
Property and equipment, net76,74983,447
Operating lease right-of-use assets75,26380,763
Restricted cash2,9212,398
Intangible assets, net5,5576,827
Goodwill118,972118,972
Other assets2,9832,064
Total assets717,682856,617
Current liabilities  
Accounts payable4,4838,084
Accrued liabilities10,15112,424
Accrued compensation and benefits10,64815,935
Current portion of operating lease liabilities9,4829,230
Current portion of deferred revenue55,34064,115
Current portion of revenue interest liability, net3,194 
Total current liabilities93,298109,788
Long-term liabilities  
Operating lease liabilities, less current portion91,82498,772
Deferred revenue, less current portion44,19458,599
Revenue interest liability, net, less current portion126,729125,360
Total liabilities356,045392,519
Commitments and contingencies (Note 9)
Shareholders’ equity  
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2023 and December 31, 2022; no shares issued and outstanding at September 30, 2023 and December 31, 2022
Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2023 and December 31, 2022; 144,772,751 and 143,105,002 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively1414
Additional paid-in capital1,436,8591,387,349
Accumulated other comprehensive loss(250)(4,116)
Accumulated deficit(1,074,891)(919,082)
Total Adaptive Biotechnologies Corporation shareholders’ equity361,732464,165
Noncontrolling interest(95)(67)
Total shareholders’ equity361,637464,098
Total liabilities and shareholders’ equity$ 717,682$ 856,617
ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
 CEO
 WEBSITEwww.adaptivebiotech.com
 EMPLOYEES790

Adaptive Biotechnologies Corp Frequently Asked Questions


What is the ticker symbol for Adaptive Biotechnologies Corp? What does ADPT stand for in stocks?

ADPT is the stock ticker symbol of Adaptive Biotechnologies Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adaptive Biotechnologies Corp (ADPT)?

As of Thu Feb 22 2024, market cap of Adaptive Biotechnologies Corp is 561.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers.

What is the fair value of ADPT stock?

You can check ADPT's fair value in chart for subscribers. The fair value of Adaptive Biotechnologies Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adaptive Biotechnologies Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adaptive Biotechnologies Corp a good stock to buy?

The fair value guage provides a quick view whether ADPT is over valued or under valued. Whether Adaptive Biotechnologies Corp is cheap or expensive depends on the assumptions which impact Adaptive Biotechnologies Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADPT.

What is Adaptive Biotechnologies Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ADPT's PE ratio (Price to Earnings) is -2.87 and Price to Sales (PS) ratio is 3.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADPT PE ratio will change depending on the future growth rate expectations of investors.